Zhitong Finance App News, Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), a subsidiary of the company's innovative pharmaceutical holding, participated in the declared “Research on a New Clinical Cure Combined Treatment Plan for Chronic Hepatitis B” project for the prevention and control of emerging outbreaks and major infectious diseases and has obtained a project completion notice issued by the Medical and Health Science and Technology Development Research Center of the National Health Commission. As a project participant, Guang Sheng Zhong Lin participated in Project 1 and Project 3 of this special hepatitis B cure project. He is responsible for the research work on the topic, and the innovative hepatitis B drugs GST-HG131, GST-HG141, and combined drugs will be used as research drugs for the project.

Zhitongcaijing · 6d ago
Zhitong Finance App News, Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), a subsidiary of the company's innovative pharmaceutical holding, participated in the declared “Research on a New Clinical Cure Combined Treatment Plan for Chronic Hepatitis B” project for the prevention and control of emerging outbreaks and major infectious diseases and has obtained a project completion notice issued by the Medical and Health Science and Technology Development Research Center of the National Health Commission. As a project participant, Guang Sheng Zhong Lin participated in Project 1 and Project 3 of this special hepatitis B cure project. He is responsible for the research work on the topic, and the innovative hepatitis B drugs GST-HG131, GST-HG141, and combined drugs will be used as research drugs for the project.